Futures, Options, OTC, Structured Products: How to Choose
Once a company decides to manage risk, the first technical question is usually: futures, options, OTC or structured products? The market often frames tools as "advanced" versus "basic", but in practice there is no better or worse tool — only fit. The same company may need different instruments across commodities, market phases and decision levels.
1. Futures: the most direct, and the most demanding of discipline
Futures solve one problem cleanly — fixing a future price today. Buying futures locks procurement cost; selling futures locks the selling price. Liquidity is good, cost is low and pricing is transparent.
But futures have a feature that is easy to overlook: they leave no room. Once price is locked, the upside is surrendered too. Futures also require margin, and adverse moves require additional funding — which places demands on cash management.
Where it fits: exposure size is clear, the direction needs to be locked, and the company can manage funding and discipline. For a company building its first hedging framework, futures are usually the right starting point.
2. Options: buy a ceiling or a floor for a known cost
Options shift the logic from "locking" to "insuring". The company pays a premium and obtains the right — not the obligation — to buy or sell at an agreed price. Upside is retained when prices move favourably; downside is protected. The cost is the premium.
That creates a psychological advantage: options do not make a company regret its decision. With futures, if the market moves favourably the hedging desk is often criticised for locking too early; options avoid this, which makes them easier to sustain inside an organisation over the long run.
Where it fits: the company wants a floor without giving up upside, or is uncertain about direction but needs a defined risk boundary.
3. OTC: tailored to a specific exposure
When exposure cannot be matched precisely with standard contracts — non-benchmark grades, unusual pricing cycles, cross-commodity exposures — over-the-counter instruments can be tailored to the actual exposure profile, avoiding the basis mismatch of standardised contracts.
But its cost must be faced squarely: counterparty credit risk. OTC contracts are not centrally cleared, so the counterparty's ability to perform is itself a risk. Using OTC requires strict counterparty onboarding and limit management, and a preference for highly rated institutions.
Where it fits: exposures standard contracts cannot cover, or hedges requiring long tenors or non-standard terms.
4. Structured combinations: balancing cost against protection
Structured solutions combine several options to reshape the cost/protection trade-off. The two most common:
- Collar: buy a put and sell a call. You give up part of the upside in exchange for a reduced or eliminated premium, locking price into a range.
- Zero-cost collar: adjust the strikes so the premium received on the sold call exactly covers the premium paid on the put, producing range protection at zero cash outlay. The trade-off is a narrower range.
The value of structures is budget certainty — finance knows in advance what the risk management spend will be, possibly zero. That is particularly attractive to companies with tight budget governance.
How to choose: three questions
Rather than memorising features, ask yourself three things:
- Are you willing to give up favourable moves? No → futures are unsuitable; consider options or a collar. Yes → futures are the cheapest and simplest structure.
- Can you absorb margin calls? No → cash-flow certainty outweighs cost; prefer premium-based solutions (paid once, no margin calls). Yes → the margin mechanism is not an obstacle.
- Is your exposure standard? Yes → exchange-traded instruments offer better liquidity and cost. No → assess OTC, and build counterparty management alongside it.
One easily missed recommendation: start simple, but know the destination
We see two extremes. One company jumps straight to the most complex structure; the team cannot understand it, the board cannot be briefed on it, and the initiative quietly dies. The other stays forever with plain futures hedging while its exposure becomes more complex, so the tool drifts further from the risk.
The more sensible path: build exposure identification and the policy framework first, then run one complete hedging cycle with futures — entry, monitoring, adjustment, exit, review — and only then decide, based on what it exposes, whether options or structured tools are warranted. Instrument upgrades should be demand-driven, not driven by looking more sophisticated.
One caution: options and structured products involve volatility and time value. A poorly chosen strike can quietly load the company with more risk than intended. These structures usually need external expertise at the design stage, and a full P&L scenario test before execution.
The above comes from what we see in real corporate diagnostics. If your company recognises itself here, we suggest a structured diagnostic session: two hours to map your exposure structure, policy gaps, instrument fit and funding arrangements in one pass, and to hand you an actionable sequence of next steps.
There is no charge for this step and no product pitch. We first need to confirm whether we can genuinely help.
